Skip to main content
    V

    Voyager Therapeutics Inc (VYGR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.52
    -0.11 (-6.75%)

    Market Cap: $107.66M

    Last updated: Nov 17, 2026 at 4:38 PM ET

    Voyager Therapeutics Inc (VYGR) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Voyager Therapeutics (VYGR) has a market cap of $107.66M and an enterprise value of $59.25M. It kept -416.32% of revenue as net income over the last 12 months. It holds $48.41M more cash than debt, 44.97% of its market cap.

    Total Valuation

    Enterprise value is 44.97% below the market cap, as cash exceeds debt.

    Market Cap$107.66M
    Enterprise Value$59.25M
    Latest price (Nov 17, 2026)$1.52

    Key Dates

    The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 8, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 2.11% in the quarter ended Sep 30, 2026 and grew 3.38% a year over 2 years.

    Shares Outstanding61.82M
    Shares Change (YoY)+5.14%
    Shares Change (QoQ)+2.11%
    Share Count Growth (2Y CAGR)+3.38%

    Valuation Ratios

    Sales and book value multiples are 3.7x and 0.7x. Its year-end P/S ranged from 1.4x to 45.8x from 2016 to 2025.

    P/S Ratio3.7x
    Forward P/S7.0x
    P/B Ratio0.7x

    Valuation history and multiples

    Price Statistics

    The stock is down 61.32% over 52 weeks and trades 34.20% below its 50-day average.

    Beta (1Y)1.52
    52-Week Change-61.32%
    1-Month Change-25.85%
    3-Month Change-55.43%
    6-Month Change-56.32%
    5-Year Change-52.49%
    10-Year Change-85.67%
    Total Return (1Y)-61.32%
    Total Return (3Y CAGR)-39.36%
    Total Return (5Y CAGR)-13.63%
    Return vs SPY (1Y)-76.05%
    Max Drawdown (1Y)-69.60%
    Max Drawdown (3Y)-85.98%
    Sharpe Ratio (1Y)-1.70
    Correlation with SPY (1Y)0.34
    50-Day Average$2.31
    200-Day Average$3.33
    52-Week Range$1.59 to $5.48
    RSI (14 Days)32.6
    Average Volume (20 Days)1.04M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 6.81x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio6.81x
    Quick Ratio6.81x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -77.37% over the last 12 months, against a 5-year average of -36.06%.

    Return on Equity (ROE)-77.37%
    Return on Assets (ROA)-59.04%
    ROE (5Y Average)-36.06%
    ROA (5Y Average)-18.43%
    ROIC (5Y Average)-66.40%
    Asset Turnover0.11x
    Receivables Turnover7.23x

    Scores

    VYGR has an Altman Z-Score of -4.06, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score-4.06
    Altman Z ZoneDistress
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $25.11M over the last 12 months is down 19.82% from the 12 months before.

    Revenue$25.11M
    Revenue Growth (YoY)-19.82%
    Gross Profit$25.11M
    Operating Income-$113.02M
    Pretax Income-$104.47M
    Net Income-$104.53M
    Reported EPS (TTM)-$1.74

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 76.31% of the $177.05M in total assets.

    Cash and Equivalents$48.41M
    Total Debt$0
    Net Cash$48.41M
    Net Cash Per Share$0.78
    Working Capital$97.62M
    Shareholder Equity$135.11M
    Book Value Per Share$2.19
    Total Assets$177.05M
    Total Liabilities$41.94M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$109.19M
    FCF Per Share-$1.78
    Depreciation and Amortization$5.00M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -450.12%.

    Gross Margin100.00%
    Operating Margin-450.12%
    Pretax Margin-416.08%
    Net Margin-416.32%

    Growth

    Revenue fell 0.44% a year over 3 years.

    Revenue Growth (3Y CAGR)-0.44%
    Revenue Growth (5Y CAGR)-25.09%
    Book Value Per Share Growth (2Y CAGR)-20.17%
    Tangible Book Per Share Growth (2Y CAGR)-20.17%

    Revenue and profit by year

    Dividends and Yields

    VYGR does not pay a dividend.

    Buyback Yield-9.61%
    Shareholder Yield-9.61%

    Analyst Forecast

    Consensus estimates put revenue growth at 5.27% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+5.27%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About VYGR

    What is VYGR's market cap?

    Voyager Therapeutics has a market cap of $107.66M. Its enterprise value, which adds debt and subtracts cash, is $59.25M.

    How many shares of VYGR are outstanding?

    Voyager Therapeutics has 61.82M shares outstanding. The count is up 5.14% from a year earlier.

    Does VYGR pay a dividend?

    No. Voyager Therapeutics does not pay a dividend.

    How much debt does VYGR have?

    Voyager Therapeutics has $0 of total debt and $48.41M of cash and equivalents, a net cash position of $48.41M.